Diaceutics PLC - Belfast-based diagnostic commercialisation firm - Signs data licensing agreement with unnamed pharmaceutical company to provide Covid-19 testing data insights in the US, enabled by DXRX - the company's diagnostics network for precision medicine.
Although the financial details of the contract cannot be disclosed, Diaceutics said the contract's value does not change management expectations for its current financial year.
"We are delighted to be able to facilitate access to this valuable Covid-tested patient cohort. This first Covid-19 data-licensing agreement for the company provides testing data insights and analytics to pharmaceutical companies actively developing treatments for the disease," said Chief Executive Officer Peter Keeling.
Current stock price: 103.60 pence
Year-to-date change: down 22%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Diaceutics (DXRX)